COMMENTARY: 900 mg daily of gabapentin was effective for hot flashes in women with breast cancer

Loprinzi, Charles L.
March 2006
ACP Journal Club;Mar/Apr2006, Vol. 144 Issue 2, p41
Academic Journal
This article reports that the well-done, large clinical trials concluded that gabapentin, at a dose of 900 mg per day in 3 divided doses, was more effective than placebo in reducing hot flashes in breast cancer survivors. The results of this trial mirror those of a study using the same dose of gabapentin in postmenopausal women who did not have breast cancer. These confirmatory results clearly identify that gabapentin moderately reduces hot flashes. The finding of virtually identical efficacy of gabapentin treatment in women with, versus without, a history of breast cancer is similar to that observed with paroxetine. Two large trials of paroxetine have been completed in women with and mostly without breast cancer.


Related Articles

  • Exemestane reduced invasive breast cancers in postmenopausal women.  // Australian Journal of Pharmacy;Dec2011, Vol. 92 Issue 1099, p78 

    The article discusses a randomised, placebo-controlled, double-blind trial of exemestane. It states that the trial is designed to detect a 65% relative reduction in invasive breast cancer. According to the study, the exemestane significantly reduced invasive breast cancers in postmenopausal...

  • Avastin Phase III Breast Cancer Trial.  // Bioworld Week;2/18/2008, Vol. 16 Issue 7, p4 

    The article reports on the result of the study conducted by Genentech Inc. which assesses the efficacy of Avastin (bevacizumab) in treating breast cancer in the U.S. The study known as AVADO was conducted through a Phase III trial which was participated by 736 HER2-negative breast cancer...

  • Highlights.  // Clinical Pharmacology & Therapeutics;May2010, Vol. 87 Issue 5, p516 

    The article offers news briefs related to cancer and its treatment. Chemotherapy is effective for breast cancer patients as it lowers the metastatic recurrence rates. The enhanced laboratory and translational clinical trial research are required to define the optimal use of placebo effects to...

  • The practical challenges of recruitment and retention when providing psychotherapy to advanced breast cancer patients. Boonzaier, Ann; Pollard, Annabel; Ftanou, Maria; Couper, Jeremy; Schofield, Penelope; Mileshkin, Linda; Henderson, Michael // Supportive Care in Cancer;Dec2010, Vol. 18 Issue 12, p1605 

    Goals of work: The goal of the present study was to investigate recruitment issues relevant to psychotherapy trials for metastatic cancer patients. First, we undertook a literature review of the psychotherapy intervention research for metastatic cancer patients. Second, we piloted pragmatic...

  • Women & Living with Breast Cancer Today.  // National Women's Health Report;Oct2005, Vol. 27 Issue 5, p1 

    The article presents information on the treatment options available for women living with breast cancer today. New treatment options, solid research and women willing to participate in clinical trials to identify better ways of screening, diagnosing and treating the disease have led to a...

  • Canadian initiatives for locally advanced breast cancer research and treatment: inaugural meeting of the Canadian Consortium for LABC. Brackstone, M.; Robidoux, A.; Chia, S.; Mackey, J.; Dent, R.; Boileau, J. F.; Clemons, M. // Current Oncology;Jun2011, Vol. 18 Issue 3, p139 

    The inaugural Canadian Consortium for LABC (locally advanced breast cancer) conference was held at Langdon Hall, Cambridge, Ontario, April 11-12, 2010. The meeting focused on current and future directions in LABC treatment and research, the specific benefits of LABC as a model for clinical and...

  • Extended Safety Profile of Oral Clodronate After Long-Term Use in Primary Breast Cancer Patients. Atula, Sari; Powles, Trevor; Paterson, Alexander; McCloskey, Eugene; Nevalainen, Jaakko; Kanis, John // Drug Safety;Jul2003, Vol. 26 Issue 9, p661 

    Introduction: Long-term safety and tolerance is paramount when treating women who are otherwise healthy after the primary adjuvant therapy of breast cancer. Efficacy and limited safety results of a large-scale clinical trial, using adjuvant oral clodronate to prevent bone metastases in primary...

  • Testosterone for low libido: Questions remain. Elliott, William T. // Travel Medicine Advisor;Jan2008 Supplement, p2 

    The article discusses the effect of testosterone on menopausal women. A research conducted on postmenopausal women, treated with testosterone patches or placebo, yielded significant increase in sexual desire and decrease in distress in the group receiving 300 milligram of testosterone per day....

  • Real-world experience with adjuvant FEC-D chemotherapy in four Ontario regional cancer centres. Madarnas, Y.; Dent, S. F.; Husain, S. F.; Robinson, A.; Alkhayyat, S.; Hopman, W. M.; Verreault, J. L.; Vandenberg, T. // Current Oncology;Jun2011, Vol. 18 Issue 3, p119 

    Background The efficacy of adjuvant chemotherapy with FEC-D (5-fluorouracil-epirubicin-cyclophosphamide followed by docetaxel) is superior to that with FEC-100 alone in women with early-stage breast cancer. As the use of FEC-D increased in clinical practice, health care providers anecdotally...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics